Collin Wetzel

Collin Wetzel

Auto-generated profile, based on publicly available information

Collin Wetzel

Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio. 1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
CBCatherine A. Behrmann
Catherine A. Behrmann
KEKelli N. Ennis
Kelli N. Ennis
PSPRANJAL SARMA
PRANJAL SARMA
CWCollin Wetzel
Collin Wetzel
NCNicholas A. Clark
Nicholas A. Clark
DPDavid R. Plas
David R. Plas
Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here, we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM. Significance: Therapy for glioblastoma would be advanced by incorporating molecularly targeted kinase-directed agents, similar to standard of care strategies in other tumor types. Here, we identify a kinase targeting approach to inhibit the metabolism and growth of glioblastoma.

11 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RVRita Verma
Rita Verma
PAParul Aggarwal
Parul Aggarwal
JRJames Reigle
James Reigle
DSDina Secic
Dina Secic
CWCollin Wetzel
Collin Wetzel
Maria F. Czyzyk-KrzeskaMaria F. Czyzyk-Krzeska
Maria F. Czyzyk-Krzeska
MAP1LC3C (LC3C) is a member of the microtubule associated family of proteins that are essential in the formation of autophagosomes and lysosomal degradation of cargo. LC3C has tumor suppressing activity and its expression is dependent on kidney cancer tumor suppressors, such as VHL and FLCN. Recently we demonstrated that LC3C autophagy is regulated by noncannonical upstream regulatory complexes and targets for degradation postdivision midbody rings associated with cancer cells stemness. Here we show that loss of LC3C leads to peripheral positioning of the lysosomes and lysosomal exocytosis (LE) in a subset of cells. This process is independent of the autophagic activity of LC3C. Analysis of isogenic cells with low and high LE shows substantial transcriptomic reprogramming with altered expression of Zn-related genes and activity of Polycomb Repressor Complex 2 (PRC2), accompanied by a robust decrease in intracellular Zn. Metabolomic analysis revealed alterations in amino acid steady-state levels. Cells with augmented LE show tumor initiation properties and form aggressive tumors in xenograft models. Immunocytochemistry identified high levels of LAMP1 on the plasma membrane of cancer cells in human ccRCC and reduced levels of Zn, an indication that LE is a frequent event in ccRCC, potentially contributing to the loss of Zn. Overall, these data indicate that an important tumor suppressing activity of LC3C is contributing to the reprogramming of lysosomal activity and Zn metabolism with implication for epigenetic remodeling in a subpopulation of tumor propagating properties of cancer cells.

28 March 2025
Verified
Other
Open access
CBCatherine A. Behrmann
Catherine A. Behrmann
KEKelli N. Ennis
Kelli N. Ennis
PSPRANJAL SARMA
PRANJAL SARMA
CWCollin Wetzel
Collin Wetzel
NCNicholas A. Clark
Nicholas A. Clark
DPDavid R. Plas
David R. Plas
Supplementary Table S2 from Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma

28 March 2025
Verified
Other
Open access
CBCatherine A. Behrmann
Catherine A. Behrmann
KEKelli N. Ennis
Kelli N. Ennis
PSPRANJAL SARMA
PRANJAL SARMA
CWCollin Wetzel
Collin Wetzel
NCNicholas A. Clark
Nicholas A. Clark
DPDavid R. Plas
David R. Plas
Supplementary Table S4 from Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma